- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Manic-Depressive Psychosis AND Mania.
Displaying page 1 of 1.
EudraCT Number: 2015-000465-31 | Sponsor Protocol Number: CannaBiD | Start Date*: 2016-06-29 | |||||||||||||||||||||||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||||||||||||||||||||||
Full Title: Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression | |||||||||||||||||||||||||||||||||
Medical condition: Bipolar disorder, current episode depressed | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004872-31 | Sponsor Protocol Number: SCA102833 | Start Date*: 2016-12-21 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003972-42 | Sponsor Protocol Number: A1281198 | Start Date*: 2020-08-21 | |||||||||||
Sponsor Name:Pfizer, Inc. | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPO... | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023740-32 | Sponsor Protocol Number: 2010-023740-32 | Start Date*: 2011-05-18 | |||||||||||
Sponsor Name:Haukeland University Hospital [...] | |||||||||||||
Full Title: Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder | |||||||||||||
Medical condition: The goal of this work is to identify genes associated with good response of bipolar patients to two commonly used mood stabilizing agents, lithium and valproate. 1. All patients will be started on ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003803-31 | Sponsor Protocol Number: PIO-BP | Start Date*: 2015-05-29 | |||||||||||
Sponsor Name:Hospital Universitario Araba (Sede Santiago) | |||||||||||||
Full Title: Adjunct pioglitazone IN THE TREATMENT OF BIPOLAR DISORDER. | |||||||||||||
Medical condition: Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011253-40 | Sponsor Protocol Number: PQ2 | Start Date*: 2009-04-23 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: Paroxetine or Quetiapine in Addition to Mood Stabilizers in Bipolar Depression | |||||||||||||
Medical condition: Major Depressive Episode in Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004088-26 | Sponsor Protocol Number: A1281201 | Start Date*: 2020-09-03 | |||||||||||
Sponsor Name:Pfizer, Inc. | |||||||||||||
Full Title: 26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC) | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002699-98 | Sponsor Protocol Number: CB001-OL | Start Date*: 2015-04-14 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: OxLith: Exploration of the short-term physical and psychological effects of lithium in mood instability | |||||||||||||
Medical condition: Bipolar disorder with current mood instability | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004023-24 | Sponsor Protocol Number: PRETEC-EPO | Start Date*: 2016-12-15 | ||||||||||||||||
Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet | ||||||||||||||||||
Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO) | ||||||||||||||||||
Medical condition: Bipolar disorder and unipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-010276-16 | Sponsor Protocol Number: F1D-MC-HGMX | Start Date*: 2009-11-19 | ||||||||||||||||
Sponsor Name:Eli Lilly | ||||||||||||||||||
Full Title: A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia | ||||||||||||||||||
Medical condition: Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000862-14 | Sponsor Protocol Number: A-bipolar | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), | |||||||||||||
Full Title: Effects of low dose Aspirin in bipolar disorder – a randomized controlled trial (the A-Bipolar RCT) | |||||||||||||
Medical condition: Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001337-40 | Sponsor Protocol Number: BXCL501-105 | Start Date*: 2021-10-05 | |||||||||||||||||||||
Sponsor Name:BioXcel Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | |||||||||||||||||||||||
Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002093-34 | Sponsor Protocol Number: NW-3509/020/III/2021 | Start Date*: 2021-11-12 | |||||||||||||||||||||
Sponsor Name:NEWRON PHARMACEUTICALS SPA | |||||||||||||||||||||||
Full Title: A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a pre... | |||||||||||||||||||||||
Medical condition: Patients with psychiatric disorders who participated in a previous trial with evenamide. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004391-21 | Sponsor Protocol Number: A1281147 | Start Date*: 2006-06-23 | |||||||||||
Sponsor Name:Pfizer S.A. | |||||||||||||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF... | |||||||||||||
Medical condition: Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Prematurely Ended) DE (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005734-20 | Sponsor Protocol Number: R076477-SCA-3002 | Start Date*: 2008-04-24 | |||||||||||
Sponsor Name:Janssen L.P. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder | |||||||||||||
Medical condition: Schizoaffective disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
